Sign in Subscribe
United States. Securities and Exchange Commission

Amgen Inc. Files SEC Form 4 Report

Strategic Insights

— 1 min read

Biotech giant Amgen Inc. filed a document with the U.S. Securities and Exchange Commission (SEC) on November 7, 2023, revealing detailed information about the company's ownership and equity securities. As a publicly traded company, Amgen Inc. is required to submit regular reports to the SEC, providing transparency into its financial dealings and corporate structure. This filing is a crucial aspect of corporate governance, enabling stakeholders to access accurate and timely information about the company's ownership dynamics.

Key Takeaways:

  • The SEC filing, Form 4, was submitted by Amgen Inc. on November 7, 2023, disclosing information about the company's ownership and equity securities.
  • The filing is a mandatory requirement for public companies, ensuring transparency and accountability in corporate dealings.
  • Amgen Inc. is a biopharmaceutical company with a significant presence in the healthcare biotechnology sector.
  • Form 4 reports provide details on the reporting person's relationship to the company, purchases, and sales of equity securities.
  • The report highlights the importance of corporate governance and the need for transparency in publicly traded companies.

Statistics:

  • One document was filed with the SEC Form 4 report.
  • The SEC filing was posted on November 7, 2023.
  • Amgen Inc. has a SIC code of 2836, indicating its involvement in the production of biological products.
  • The company's contact information is listed as One Amgen Center Drive, Thousand Oaks, CA 91320, with a phone number of (805) 447-1000.

Sources:

  • U.S. Securities and Exchange Commission (SEC) filing by Amgen Inc. (Form 4), posted on November 7, 2023.
  • NewsRx, a leading provider of fact-based news and research discoveries, reporting on the SEC filing by Amgen Inc.

Read more